David D. Meek's most recent trade in uniQure N.V. was a trade of 2,112 Ordinary Shares done at an average price of $14.4 . Disclosure was reported to the exchange on June 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| uniQure N.V. | David D. Meek | Director | Sale of securities on an exchange or to another person at price $ 14.45 per share. | 20 Jun 2025 | 2,112 | 34,190 (0%) | 0% | 14.4 | 30,518 | Ordinary Shares |
| Cullinan Oncology Inc | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 38,513 | 38,513 | - | - | Stock Option (Right to Buy) | |
| Trevi Therapeutics Inc | David P. Meeker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 45,000 | 45,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 15,630 | 15,630 | - | - | Stock Option (Right to Buy) | |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 7,970 | 36,302 (0%) | 0% | 0 | Ordinary Shares | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2025 | 43,620 | 0 | - | - | Stock Option (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.59 per share. | 03 Jun 2025 | 43,620 | 245,445 (0%) | 0% | 4.6 | 200,216 | Common Stock |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 65.04 per share. | 03 Jun 2025 | 43,346 | 202,099 (0%) | 0% | 65.0 | 2,819,358 | Common Stock |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 65.60 per share. | 03 Jun 2025 | 274 | 201,825 (0%) | 0% | 65.6 | 17,975 | Common Stock |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 200,000 | 200,000 | - | - | Stock Options (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 133,350 | 133,350 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 21,250 | 63,750 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 21,250 | 211,177 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 57.22 per share. | 14 Feb 2025 | 9,896 | 201,281 (0%) | 0% | 57.2 | 566,249 | Common Stock |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 14,125 | 194,205 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 14,125 | 28,250 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 59.43 per share. | 01 Feb 2025 | 4,278 | 189,927 (0%) | 0% | 59.4 | 254,242 | Common Stock |
| Trevi Therapeutics Inc | David P. Meeker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 27 Aug 2024 | 4,555 | 357,044 (2%) | 0% | 1.4 | 6,514 | Common Stock |
| Trevi Therapeutics Inc | David P. Meeker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2024 | 4,555 | 0 | - | - | Stock Option (right to buy) | |
| Trevi Therapeutics Inc | David P. Meeker | Director | Sale of securities on an exchange or to another person at price $ 2.93 per share. | 27 Aug 2024 | 4,555 | 352,489 (1%) | 0% | 2.9 | 13,353 | Common Stock |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2024 | 15,840 | 15,840 | - | - | Stock Option (Right to Buy) | |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2024 | 8,080 | 28,332 (0%) | 0% | 0 | Ordinary Shares | |
| Trevi Therapeutics Inc | David P. Meeker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| uniQure N.V. | David D. Meek | Director | Sale of securities on an exchange or to another person at price $ 5.12 per share. | 13 Jun 2024 | 2,229 | 20,252 (0%) | 0% | 5.1 | 11,412 | Ordinary Shares |
| Cullinan Oncology Inc | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 15,618 | 15,618 | - | - | Stock Option (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 39.22 per share. | 19 Mar 2024 | 45,494 | 174,605 (0%) | 0% | 39.2 | 1,784,275 | Common Stock |
| Rhythm Pharmaceuticals Inc. | David Meeker P. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 259,000 | 259,000 | - | - | Stock Option (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | P. David Meeker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 99,000 | 220,099 (0%) | 0% | 0 | Common Stock | |
| Rhythm Pharmaceuticals Inc. | Meeker David P. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 85,000 | 85,000 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | Meeker David P. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 14,125 | 42,375 | - | - | Restricted Stock Units | |
| Rhythm Pharmaceuticals Inc. | P. David Meeker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 14,125 | 125,460 (0%) | 0% | - | Common Stock | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.06 per share. | 01 Feb 2024 | 4,361 | 121,099 (0%) | 0% | 45.1 | 196,507 | Common Stock |
| Trevi Therapeutics Inc | David P. Meeker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 17,060 | 17,060 | - | - | Stock Option (Right to Buy) | |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 8,700 | 24,771 (0%) | 0% | 0 | Ordinary Shares | |
| uniQure N.V. | David D. Meek | Director | Sale of securities on an exchange or to another person at price $ 18.85 per share. | 13 Jun 2023 | 2,290 | 22,481 (0%) | 0% | 18.9 | 43,167 | Ordinary Shares |
| uniQure N.V. | David D. Meek | Director | Sale of securities on an exchange or to another person at price $ 19.71 per share. | 27 Feb 2023 | 389 | 16,071 (0%) | 0% | 19.7 | 7,667 | Ordinary Shares |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 229,600 | 229,600 | - | - | Stock Option (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 56,500 | 56,500 | - | - | Restricted Stock Units | |
| Mirati Therapeutics Inc | David D. Meek | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 151,233 | 151,233 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | David D. Meek | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 89,379 | 151,171 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | David D. Meek | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.38 per share. | 17 Jan 2023 | 3,179 | 61,792 (0%) | 0% | 42.4 | 134,715 | Common Stock |
| Mirati Therapeutics Inc | David D. Meek | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2022 | 35,425 | 69,587 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | David D. Meek | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 40.41 per share. | 19 Dec 2022 | 4,616 | 64,971 (0%) | 0% | 40.4 | 186,552 | Common Stock |
| Trevi Therapeutics Inc | David P. Meeker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 17,810 | 17,810 | - | - | Stock Option (Right to Buy) | |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 9,080 | 16,460 (0%) | 0% | 0 | Ordinary Shares | |
| uniQure N.V. | David D. Meek | Director | Sale of securities on an exchange or to another person at price $ 16.70 per share. | 28 Feb 2022 | 602 | 7,380 (0%) | 0% | 16.7 | 10,053 | Ordinary Shares |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 2,645 | 2,645 | - | - | Stock Option (Right to Buy) | |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 1,534 | 7,982 (0%) | 0% | 0 | Ordinary Shares | |
| Mirati Therapeutics Inc | David D. Meek | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 56,433 | 56,433 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | David D. Meek | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 34,057 | 34,057 (0%) | 0% | 0 | Common Stock | |
| Trevi Therapeutics Inc | David P. Meeker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 20.17 per share. | 30 Mar 2021 | 10,000 | 111,335 (0%) | 0% | 20.2 | 201,713 | Common Stock |
| uniQure N.V. | David D. Meek | Director | Sale of securities on an exchange or to another person at price $ 37.50 per share. | 02 Mar 2021 | 505 | 6,448 (0%) | 0% | 37.5 | 18,938 | Ordinary Shares |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 4,107 | 4,107 | - | - | Stock Option (Right to Buy) | |
| uniQure N.V. | David D. Meek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 2,382 | 6,953 (0%) | 0% | 0 | Ordinary Shares | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 220,000 | 220,000 | - | - | Stock Option (right to buy) | |
| Rhythm Pharmaceuticals Inc. | David P. Meeker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2020 | 900,000 | 900,000 | - | - | Stock Option (right to buy) |